EurekaMag.com logo
+ Site Statistics
References:
52,725,316
Abstracts:
28,411,598
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on Google+Follow on Google+
Follow on LinkedInFollow on LinkedIn

+ Translate

Evaluation of a new halcinonide formulation in the treatment of common dermatoses


Cutis 30(2): 262-266
Evaluation of a new halcinonide formulation in the treatment of common dermatoses
An open evaluation of halcinonide 0.1 percent in a hydrophilic vanishing cream base was conducted in one hundred patients with common steroid-responsive dermatoses, including eczema, contact dermatitis, atopic dermatitis stasis dermatitis, and neurodermatitis. Patients applied the cream two or three times a day for two weeks (or less if the clinical response warranted earlier discontinuation). Follow-up assessments were made on days 4, 7, and 14 of the study. Ninety-eight percent of the patients showed some degree of improvement, and eighty-five percent had complete clearing or marked improvement. One patient had no response and one worsened. Seventy-seven percent of the patients who responded achieved their maximum response within the first week of treatment. One case of urticaria was the only side effect noted in this series. Ninety-six percent of the patients rated their acceptance of the new formulation as excellent or good.


Accession: 005395379

PMID: 7128207



Related references

Evaluation of a topical steroid antibiotic combination (halcinonide-neomycin-amphotericin) in the treatment of cutaneous candidiasis and inflammatory dermatoses. Current Medical Research and Opinion 5(10): 766-771, 1979

Clinical comparison of halcinonide and betamethasone valerate in common dermatoses. Australasian Journal of Dermatology 16(1): 17-19, 1975

Halcinonide in the treatment of corticosteroid responsive dermatoses. British Journal of Dermatology 90(4): 435-440, 1974

Comparison of 0.1% halcinonide with 0.05% betamethasone dipropionate in the treatment of acute and chronic dermatoses. Current Medical Research and Opinion 5(4): 328-332, 1977

Efficacy of halcinonide cream, 0.1 percent, in the treatment of moderate and severe dermatoses. Cutis 27(4): 433-435, 1981

Topical treatment of inflammatory dermatoses and cutaneous candidiasis with a new cortico-steroid-antibiotic combination: halcinonide-neomycin-amphotericin. British Journal of Clinical Practice 31(4): 33-35, 1977

A comparative clinical evaluation of a new topical steroid 'halcinonide' and hydrocortisone in steroid-responsive dermatoses. Journal of International Medical Research 4(4): 228-231, 1976

Comparative efficacy of halcinonide and fluocinonide creams in psoriasis and eszematous dermatoses. Journal of Clinical Pharmacology 15(11-12): 779-784, 1975

Comparative efficacy of halcinonide and flucinonide creams in psoriasis and eczematous dermatoses. Journal of Clinical Pharmacology 15(11-12): 779-784, 1975

Evaluation of topical and internal medications containing essential unsaturated fatty acids in treatment of common dermatoses. Clinical Medicine 69: 898-900, 1962